6-bromo-1-(4-hydroxyphenyl)-1-hexanone | 188973-67-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-bromo-1-(4-hydroxyphenyl)-1-hexanone
• 英文别名: 6-bromo-1-(4-hydroxyphenyl)hexan-1-one
• CAS: 188973-67-3
• 化学式: C₁₂H₁₅BrO₂
• 分子量: 271.154
• InChiKey: MUSYWXAUDRCNOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-甲氧苯基)哌嗪 、 6-bromo-1-(4-hydroxyphenyl)-1-hexanone 以 乙腈 为溶剂， 以42%的产率得到1-(4-Hydroxy-phenyl)-6-[4-(2-methoxy-phenyl)-piperazin-1-yl]-hexan-1-one
  参考文献：
  名称：

  Synthesis and Structure−Affinity Relationships of 1-[ω-(4-Aryl-1-piperazinyl)alkyl]-1-aryl Ketones as 5-HT₇ Receptor Ligands

  摘要：

  Structural requirements for 5-HT7 receptor affinity and selectivity over that for the 5-HT1A receptor were studied on a series of 1-[omega-(4-aryl-1-piperazinyl)alkyl] - I-aryl ketones. The presence of a hydroxy or methoxy substituent on aryl ketone moiety, alkyl chain length, and the nature of N-1-piperazine substituent were explored. 6-[4-(3-Benzisoxazolyl)-l-piperazinyl]-1-(2-hydroxyphenyl)-1-hexanone (40) and its methoxy analogue 43 exhibited high 5-HT7 receptor affinities (K-i = 2.93 nM and 0.90 nM, respectively) and agonist properties when tested for 5-HT7 receptor-mediated relaxation of substance P-induced guinea-pig ileum contraction.

  DOI：

  10.1021/jm020994z
• 作为产物：
  描述：

  6-溴己酰氯 、 苯酚 在 三氯化铝 作用下， 以 二氯甲烷 为溶剂， 生成 6-bromo-1-(4-hydroxyphenyl)-1-hexanone
  参考文献：
  名称：

  苯甲酰胺衍生物作为选择性5-羟色胺4受体激动剂的合成及其药理特性。

  摘要：

  合成了一系列在哌啶环的1-位具有极性取代基的4-氨基-5-氯-2-甲氧基-N-（哌啶-4-基甲基）苯甲酰胺，并评估了其对胃肠动力的影响。苯甲酰基，苯磺酰基和苄基磺酰基衍生物加速胃排空并增加排便频率。其中一种是选择性的5-HT 4，即4-氨基-N- [1- [3- [苄基磺酰基）丙基]哌啶-4-基甲基] -5-氯-2-甲氧基苯甲酰胺（13a，Y-36912）。受体激动剂具有潜力，可作为一种新型的促运动药物，具有降低的由5-HT3-和多巴胺D2受体结合亲和力产生的副作用。在口服给药途径中，该化合物可增强小鼠的胃排空和排便能力，并有可能作为促运动剂，

  DOI：

  10.1016/j.bmc.2004.02.036

文献信息

• Benzoic acid compounds and use thereof as medicaments
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05864039A1

  公开（公告）日：1999-01-26

  Benzoic acid compounds of the formula ##STR1## wherein each symbol is as defined in the specification, optical isomers thereof and pharmaceutically acceptable salts thereof; pharmaceutical composition comprising this compound and pharmaceutically acceptable additive; and serotonin 4 receptor agonists, gastrointestinal prokinetic agents and therapeutic agents for various gastrointestinal diseases, which comprise this compound as active ingredient. The compounds of the present invention have high and selective affinity for serotonin 4 receptor, and show agonistic effects thereon. Accordingly, they are useful medications for the prophylaxis and treatment of various gastrointestinal diseases, central nervous disorders, cardiac function disorders, urinary diseases, and the like, as well as useful anti-nociceptors for analgesic use which increase threshold of pain.

  苯甲酸化合物的化学式为##STR1##，其中每个符号如规范中定义，其光学异构体及其药用可接受盐；包括该化合物和药用可接受添加剂的药物组合物；以及将该化合物作为活性成分的5-羟色胺4受体激动剂、胃肠促动力剂和用于各种胃肠疾病的治疗剂。本发明的化合物具有对5-羟色胺4受体的高度和选择性亲和力，并显示出激动效应。因此，它们可用于预防和治疗各种胃肠疾病、中枢神经障碍、心脏功能障碍、泌尿系统疾病等，同时还可用作提高疼痛阈值的镇痛用途的有用抗痛觉剂。
• BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0873990A1

  公开（公告）日：1998-10-28

  A benzoic acid compound of the formula wherein each symbol is as defined in the specification, an optical isomer thereof and a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising this compound and a pharmaceutically acceptable additive, a serotonin 4 receptor agonist comprising this compound as an active ingredient, a gastrointestinal prokinetic agent and a therapeutic agent for gastrointestinal diseases. The compound of the present invention shows selective and high affinity for serotonin 4 receptors, activates same, is useful as a pharmaceutical agent for the prophylaxis and treatment of gastrointestinal diseases (e.g., reflux esophagitis; gastroesophageal reflux such as that accompanying cystic fibrosis; Barrett syndrome; intestinal pseudoileus; acute or chronic gastritis; gastric or duodenal ulcer; Crohn's disease; non-ulcer dyspepsia; ulcerative colitis; postgastrectomy syndrome; postoperative digestive function failure; delayed gastric emptying caused by gastric neurosis, gastroptosis, diabetes, and the like; gastrointestinal disorders such as indigestion, meteorism, abdominal indefinite complaint, and the like; constipation such as atonic constipation, chronic constipation, and that caused by spinal cord injury, pelvic diaphragm failure and the like; and irritable bowel syndrome), central nervous disorders (e.g., schizophrenia, depression, anxiety, disturbance of memory and dementia), cardiac function disorders (e.g., cardiac failure and myocardial ischemia), urinary diseases (e.g., dysuria caused by urinary obstruction, ureterolith, prostatomegaly, spinal cord injury, pelvic diaphragm failure, etc.), and shows superior absorption.

  式中的苯甲酸化合物 其中各符号如说明书中所定义，其光学异构体及其药学上可接受的盐。由该化合物和药学上可接受的添加剂组成的药物组合物、以该化合物为活性成分的血清素 4 受体激动剂、胃肠促动力药和胃肠疾病治疗剂。 本发明的化合物对 5-羟色胺 4 受体具有选择性和高亲和力，能激活 5-羟色胺 4 受体，可用作预防和治疗胃肠道疾病（如反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎）的药物、反流性食管炎；胃食管反流，如伴随囊性纤维化的胃食管反流；巴雷特综合征；肠道假膜；急性或慢性胃炎；胃或十二指肠溃疡；克罗恩病；非溃疡性消化不良；溃疡性结肠炎；胃切除术后综合征；术后消化功能衰竭；胃神经官能症、胃下垂、糖尿病等引起的胃排空延迟；消化不良、陨石症、腹部不适等胃肠道疾病；失张性便秘、慢性便秘、脊髓损伤引起的便秘、骨盆膈肌功能衰竭等便秘；肠易激综合征）、中枢神经紊乱（如溃疡性结肠炎g.,精神分裂症、抑郁症、焦虑症、记忆障碍和痴呆症）、心脏功能紊乱（如心力衰竭和心肌缺血）、泌尿系统疾病（如尿路梗阻、输尿管结石、前列腺肥大、脊髓损伤、盆腔膈肌衰竭等引起的排尿困难），并显示出良好的吸收性。
• EP873990
  申请人：——

  公开号：——

  公开（公告）日：——
• US5864039A
  申请人：——

  公开号：US5864039A

  公开（公告）日：1999-01-26
• Synthesis and Structure−Affinity Relationships of 1-[ω-(4-Aryl-1-piperazinyl)alkyl]-1-aryl Ketones as 5-HT₇ Receptor Ligands
  作者：Roberto Perrone、Francesco Berardi、Nicola A. Colabufo、Enza Lacivita、Marcello Leopoldo、Vincenzo Tortorella

  DOI：10.1021/jm020994z

  日期：2003.2.1

  Structural requirements for 5-HT7 receptor affinity and selectivity over that for the 5-HT1A receptor were studied on a series of 1-[omega-(4-aryl-1-piperazinyl)alkyl] - I-aryl ketones. The presence of a hydroxy or methoxy substituent on aryl ketone moiety, alkyl chain length, and the nature of N-1-piperazine substituent were explored. 6-[4-(3-Benzisoxazolyl)-l-piperazinyl]-1-(2-hydroxyphenyl)-1-hexanone (40) and its methoxy analogue 43 exhibited high 5-HT7 receptor affinities (K-i = 2.93 nM and 0.90 nM, respectively) and agonist properties when tested for 5-HT7 receptor-mediated relaxation of substance P-induced guinea-pig ileum contraction.